Ixekizumab

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1367 publications

Successful treatment of recalcitrant Hailey-Hailey disease with ixekizumab.

Successful treatment of recalcitrant Hailey-Hailey disease with ixekizumab.

Journal: JAAD case reports

Published: June 12, 2026

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.

Journal: JAMA dermatology

Published: May 15, 2026

IL-17 inhibitor therapy and risk of chronic obstructive pulmonary disease and related pulmonary outcomes in patients with psoriasis: A real-world cohort study.

IL-17 inhibitor therapy and risk of chronic obstructive pulmonary disease and related pulmonary outcomes in patients with psoriasis: A real-world cohort study.

Journal: Respiratory medicine

Published: May 07, 2026

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity.

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: May 01, 2026

Interleukin-17A inhibitors for guttate psoriasis treatment: A retrospective cohort study.

Interleukin-17A inhibitors for guttate psoriasis treatment: A retrospective cohort study.

Journal: JAAD international

Published: April 13, 2026

Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study.

Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study.

Journal: Dermatology and therapy

Published: April 07, 2026

Eruptive Lentiginosis Within Resolved Psoriasis Plaques: A Case Report and Systematic Review of the Literature.

Eruptive Lentiginosis Within Resolved Psoriasis Plaques: A Case Report and Systematic Review of the Literature.

Journal: Journal of drugs in dermatology : JDD

Published: April 03, 2026

Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators.

Comparative risk of psoriatic arthritis in psoriasis patients on immunomodulators.

Journal: Proceedings (Baylor University. Medical Center)

Published: March 16, 2026

PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.

PDE4 inhibition in pediatric psoriasis: analysis of the SPROUT study on apremilast.

Journal: Expert opinion on pharmacotherapy

Published: March 14, 2026

Bullous Pemphigoid Possibly Induced by Deucravacitinib in a Patient with Psoriasis.

Bullous Pemphigoid Possibly Induced by Deucravacitinib in a Patient with Psoriasis.

Journal: Clinical, cosmetic and investigational dermatology

Published: March 06, 2026

Prior Specific Biologic Use as a Potential Risk Factor for Administration-related Reactions to Ixekizumab after Excipient Modification: A Single-centre Retrospective Study.

Prior Specific Biologic Use as a Potential Risk Factor for Administration-related Reactions to Ixekizumab after Excipient Modification: A Single-centre Retrospective Study.

Journal: Acta dermato-venereologica

Published: March 03, 2026

Psoriasis Flare Following Interleukin-17 (IL-17) Inhibition and Recent Streptococcal Infection: A Case Report Highlighting Management Complexity.

Psoriasis Flare Following Interleukin-17 (IL-17) Inhibition and Recent Streptococcal Infection: A Case Report Highlighting Management Complexity.

Journal: Cureus

Published: March 02, 2026

Showing 1-12 of 1,367

Last Updated: 06/30/2026